Quick orientationEvidence update: 6 October 2026
What is Ipamorelin?
Ipamorelin is a selective agonist of the ghrelin or growth-hormone-secretagogue receptor. In plain English, it presses a receptor that tells the pituitary to release growth hormone.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Human studies have examined GH release and, in a different clinical setting, postoperative gastrointestinal recovery.
What the mechanism suggests
Selective ghrelin/GHSR agonist developed as a growth-hormone secretagogue.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Selective ghrelin/GHSR agonist developed as a growth-hormone secretagogue.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Post-operative ileus proof-of-concept trial — 2014
Multicentre double-blind placebo-controlled trial · 114 analysedIpamorelin 0.03 mg/kg IV twice daily after bowel resection shortened median time to first tolerated meal numerically (25.3 vs 32.6 hours), but the difference was not statistically significant (p=0.15).
There is human trial experience, but it was in post-operative gut recovery—not sleep, fat loss or gym recovery.
What it doesn't prove: Different route, dose and indication from wellness use; efficacy endpoint missed significance.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Healthy-volunteer PK/PD | IV infusion rates 4.21, 14.02, 42.13, 84.27 or 140.45 nmol/kg over 15 min | Single experimental exposure | Dose-escalation cohorts | Human PK/PD |
| Human PK result | Terminal half-life ~2 hours | — | — | Human PK/PD |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Lower pattern | 100 mcg SC once daily, often bedtime | 8–12 weeks | Often starting point | Community |
| Most recurring | 200–300 mcg SC per dose | Once or twice daily | May increase from 100 | Community |
| Higher/frequent pattern | 100–300 mcg per dose | Up to 3× daily | No validated ladder | Community |
| Cycle convention | 100–300 mcg/dose | 8–12 weeks; ~4 weeks off often cited | Some 5-on/2-off clinic patterns | Community/clinic |
Human ipamorelin data demonstrate acute GH pharmacology, not the efficacy or safety of chronic 100–300 mcg SC community protocols.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Physiological GH release does not prove general anti-ageing or recovery benefits.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
There is human trial experience, but it was in post-operative gut recovery—not sleep, fat loss or gym recovery.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.